What's driving AstraZeneca higher today?

Traders Union
All News
Financial News
AstraZeneca gains 0.83% to GBX14,166

Highlights

The European Commission approved Enhertu for HER2-positive metastatic solid tumors, expanding AstraZeneca’s oncology portfolio in Europe.
This regulatory milestone grants AstraZeneca access to a larger patient population, positioning for near-term revenue growth from broader commercial uptake.
AZN/GBX trades below short-term moving averages with indicators signaling oversold momentum; price projected within GBX13,758–GBX14,545, favoring further downside.

Oncology portfolio expands as EU approval boosts market reach

The European Commission has approved Enhertu for treating HER2-positive metastatic solid tumors, granting AstraZeneca access to a broader patient population in Europe, as reported by Tradingkey. This regulatory milestone enables the company to expand its oncology portfolio and could drive near-term commercial uptake of the drug. With new treatment options available in the region, the approval sets the stage for increased market penetration and revenue growth.

Oversold momentum persists as price tests resistance and diverging signals

On the technical front, AZN/GBX is trading below the MA-20 at GBX14,353 and MA-50 at GBX14,260 on the H1 chart, while remaining above the MA-200 at GBX13,738 on the daily timeframe. Immediate resistance is defined by the Ichimoku Kijun level at GBX14,301. The Relative Strength Index (RSI) signals a sell, with Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power all reflecting oversold conditions, confirming strong selling momentum intraday. The Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) are both neutral, while the Awesome Oscillator does not provide a clear directional cue. Divergence between neutral momentum indicators and persistent oversold oscillator readings suggests the current decline may pause before trend strength resumes.

Range-bound trade likely as downside risks outweigh bullish breakout

Over the next few days, price action is projected to remain within the GBX13,758 to GBX14,545 volatility band relative to current levels. There is a 40% probability of an upward move versus a 60% chance of continued downside pressure, so further short-term declines are more likely. The baseline scenario is sideways movement within this range, with a bullish breakout contingent on price clearing immediate resistance at the Ichimoku Kijun. If price falls below the lower band, a deeper retracement could materialize.

Anton Kharitonov, expert at Traders Union, sees the recent European Commission approval for Enhertu as a fundamental positive but does not expect immediate upside for AstraZeneca shares. He notes technical momentum is still weak, with price action capped below several moving averages and short-term signals pointing to further downside risk. The analyst expects range-bound movement, with any bullish case hinging on a sustained break above GBX14,301. "I remain cautious here — until we see a clear reversal above resistance, the setup favors sellers."

Earlier, analysts noted that AstraZeneca had sustained its technical resilience and fundamental momentum despite ongoing regulatory approvals and partnerships. Currently, while strong selling pressure dominates and key moving averages have turned from support to resistance, traders should monitor for a shift in momentum that could trigger a reversal if price recaptures the Ichimoku Kijun, as this level now defines the outlook for short-term direction.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.